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Background: Plasmodium vivax is the most widespread of the malaria parasites infecting human hosts. In
malaria-eliminating settings, both imported and local malaria predominantly occurs in border areas, and most of
them are P. vivax. Chloroquine (CQ) is the first-line drug for P. vivax treatment in China. To understand CQ sensitivity in
P. vivax, in vivo monitoring of CQ resistance was conducted along the China-Myanmar border from 2008 to 2013.
Methods: Eligible patients with mono-infections of P. vivax were recruited to this study after obtaining full informed
consent. CQ tablets for different categories of kg body weight ranges were given once a day for three days. Patients
were followed up for 28 days. PCR was conducted to distinguish between re-infection and recrudescence, to confirm
the Plasmodium species. The data were entered and analysed by the Kaplan-Meier method. Treatment outcome and
sensitivity were classified according to the WHO recommended standards.
Results: 603 patients were completed valid follow-up. The fever clearance time and asexual parasite clearance times
were, respectively, 22.2 ± 10.2 and 38.1 ± 12.6 hours. 594 (98.5%) patients were adequate clinical and parasitological
response (ACPR), and nine (1.5%) patients, who were late clinical failure (LCF) or resistant response level I (RI), were
imported from the neighbouring districts of Myanmar.
Conclusion: In terms of efficacy, CQ is still effective for vivax malaria treatment. Plasmodium vivax CQ sensitivity had
not significantly changed along the China-Myanmar border of Yunnan Province, China.
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Malaria is still a global public health problem. The World
Health Organization (WHO) estimated that between 2000
and 2010, global malaria incidence decreased by 17% and
malaria-specific mortality rates decreased by 26%. Re-
ported malaria cases have reduced by more than 50% in
34 of the 99 malaria-endemic countries [1]. China has de-
clared a national policy for malaria elimination by 2020
[2,3]. In eliminating settings, malaria predominantly oc-
curs in border areas, and imported cases tend to make up
the majority of recorded cases caused by Plasmodium
vivax [4]. Resistance to anti-malarial drugs has often
threatened malaria elimination efforts and historically has* Correspondence: yang_henglin@sohu.com; xjw426@163.com
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unless otherwise stated.led to the short-term resurgence of malaria incidence and
deaths [5]. This can jeopardize progress and investment in
combating malaria [6]. Plasmodium vivax is the most
widespread of the malaria parasites infecting human hosts.
Although there were an estimated 72–80 million P. vivax
infections each year, it has not received as much public
and scientific attention as Plasmodium falciparum [7]. In
fact, P. vivax can lead to a disabling disease that can be
fatal, and exacts a similar economic burden as falciparum
malaria [8]. Finding and treating the P. vivax infection to
prevent onward transmission is the determinant interven-
tion. Chloroquine (CQ)-resistant P. vivax was first de-
scribed in 1989 in Papua New Guinea [9], and the decline
in the efficacy of CQ has been reported in some geograph-
ical sites [10]. CQ is the first-line drug for P. vivaxThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CQ is the basis of vivax malaria treatment with CQ.
Knowledge of drug sensitivity is also needed to guide the
local drug policy, so WHO strongly encourages countries
in which P. vivax is endemic to carry out pilot studies to
monitor the efficacy of CQ [11]. From 2008 to 2013,
in vivo monitoring of CQ resistance in P. vivax was con-
ducted to determine the dynamics of P. vivax sensitivity to
CQ in the field along the China-Myanmar border.Methods
Surveillance sites and time
Surveillance was carried out in Tengchong and Yangjiang,
two counties on the China-Myanmar border (Figure 1).
One of the main reasons for this selection of surveillance
sites was that suitable vivax malaria patients were difficult
to find in other parts of China. Most of the malaria cases
in the two counties were imported from neighbouring dis-
tricts of Myanmar. The surveillance activities were con-
ducted in Tengchong County in 2008 and 2009, and
expanded to Yingjiang County in 2010 and 2011, and only
carried out in Yingjiang County because of so few malaria
cases in Tengchong in 2012 and 2013.Figure 1 The location of Tengchong and Yingjiang counties relative tPatients and recruiting criteria
Patients whose axillary temperature was ≥37.5°C or his-
tory of fever during the previous 24 hours were diag-
nosed based on microscopy of thick and thin blood
smears. Patients with mono-infections of P. vivax were
recruited to this study after obtaining full informed con-
sent. Only patients older than one year presenting with
parasite density 500–120,000 parasites per μL were en-
rolled into the study. Imported malaria was identified as
patients who had traveled from endemic areas of
Myanmar within one month and were diagnosed as mal-
aria in China [3]. Patients were excluded from the study
if any of the following criteria were present: (1) positive
pregnancy test or breastfeeding; (2) complicated malaria;
(3) having taken any anti-malarial, sulpha, tetracycline
and sulphone drugs within the previous seven days; (4)
history of hypersensitivity to any of the study drugs; (5)
severe dysfunction with kidney, liver and heart; (6) over
60 years old; and, (7) unable to follow up.
Drug and administration
CQ (GYZZ H31020423, 155 mg base per tablet) was made
by Shanghai Sino-West Pharmaceutical Corp, China, and
provided by The West Pacific Office of World Healtho neighbouring countries.
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for three days. The doses were recommended by
WPRO/WHO too. For convenient administration of the
drugs, the doses were calculated into tablets for differ-
ent categories of kg body weight ranges (Table 1) [12].
Based on the recommendation of the China Ministry of
Health, a standard adult (≥16 years) dosage of prima-
quine tablets (22.5 mg/day) was given for treatment of
liver-stage parasites over eight days after completion of
28-day follow-up. The age based dosing was used for chil-
dren, 3.75-5.625 mg/day for age 1–3 years, 7.5 mg/day for
age 4–6 years, 11.25 mg/day for age 7–12 years and
16.875 mg/day for age 13–15 years over eight days [12].
Laboratory and in vivo clinical monitoring
Parasite microscopy was conducted on admission and
every 12 hours while the patients stayed in hospital over
the following seven days. Then patients were discharged
from hospital and further parasitological examinations
were performed on days 14, 21 and 28. Malaria blood
films were stained with Giemsa and parasites were
counted per 500 white blood cells. The number of para-
sites was calculated as per ul of blood by the level of
8,000 of leukocyte per ul [13]. A filter-paper dried blood
spot (about 100 ul blood) was prepared on admission,
days 3, 7, 14, 21, and 28 for polymerase chain reaction
(PCR) to distinguish between re-infection and recrudes-
cence, to confirm the Plasmodium species or to detect
mixed infection. Improved Chelex 100 ion exchange
method was used to extract DNA from blood filter paper
samples, nested PCR and allele specific PCR techniques,
agarose gel electrophoresis analysis and dot/southern
blotting probe hybridization were employed for amplifi-
cation, resolution and identification of the circumsporo-
zoite protein (CSP) gene to distinguish reinfection from
recrudescence or relapse. The primary PCR primers
were 5′- TCCCCACGCACTGCAAAC ACAAT-3′ (F)
and 5′- CCGCAGGAGGTGCCACGTATAATT-3′(R). The
secondary PCR primers were 5′- GAAAATAAGCTGAA
ACAAC-3′ (F) and 5′-TACGTCACATTGGAC ACCT-3′
(R) [14]. In case of failure after day 7, patients whose PCR
results were unknown would be excluded from the analysisTable 1 Number of chloroquine tablets (155 mg base per











Day 1 Day 2 Day 3
≤ 12 1 0.5 0.5 2
13-24 2 1 1 4
24.1- 36 3 1.5 1.5 6
36.1- 48 4 2 2 8
>48 5 2.5 2.5 10in accordance with the standardized WHO protocol [11].
The treatment outcome was assessed on the basis of para-
site clearance from the blood. Parasite clearance was de-
fined as no parasite per 500 white blood cells by two
continuous every 12-hour microscopy. The primary end-
point was the 28-day cure rate. Cure was defined as elimin-
ation of the symptoms and asexual blood stages of the
malaria parasites that caused the patient to seek treatment.
Fever clearance was defined as axillary temperatures < 37.1°
C in duration of 24 hours [15].
Classification standards for treatment outcome
and sensitivity
Treatment outcome was categorized based on the WHO
definitions for early treatment failure (ETF), late clinical
failure (LCF), late parasitological failure (LPF), and ad-
equate clinical and parasitological response (ACPR). The
ETF definition was to conform to any one of the criteria:
(1) danger signs or severe malaria on day 1, 2 or 3, in the
presence of parasitaemia; (2) parasitaemia on day 2 higher
than on day 0, irrespective of axillary temperature; (3)
parasitaemia on day 3 with axillary temperature ≥37.5°C;
and, (4) parasitaemia on day 3 ≥ 25% of count on day 0.
The LCF definition was to satisfy any one of the criteria:
(1) danger signs or severe malaria in the presence of para-
sitaemia on any day between day 4 and day 28 in patients
who did not previously meet any of the criteria of ETF;
and, (2) presence of parasitaemia on any day between day
4 and day 28 with axillary temperature ≥37.5°C in patients
who did not previously meet any criteria of ETF. LPF defin-
ition was to satisfy presence of parasitaemia on any day be-
tween day 7 and day 28 with axillary temperature <37.5°C
in patients who did not previously meet any of the criteria
of ETF or LCF. ACPR definition was to satisfy absence of
parasitaemia on day 28, irrespective of axillary temperature,
in patients who did not previously meet any criteria of ETF,
LCF or LPF [11].
Resistant responses (S, RI–RIII) were categorized ac-
cording to the WHO criteria [13]. Susceptible parasites
(S) were defined if asexual stage parasites had a ≥75% re-
duction within 48 hours after drug treatment and slides
were negative for two consecutive days within seven
days, and no recrudescence occurred within the 28-day
follow-up period. RI definition was 75% reduction in
parasitaemia within 48 hours after initiation of therapy
and parasite clearance within seven days but recrudes-
cence within 28 days; RII was ≥75% reduction of initial
parasitaemia within 48 hours of drug treatment, but
without parasite clearance within seven days; RIII was
parasitaemia ≥25% of initial parasite count at 48 hours
after initiation of therapy. Patients with resistant para-
sites (RI-RIII) were subsequently given a standard adult
dosage of dihydroartemisinin-piperaquine tablets fol-
lowing the Ministry of Health recommended two-day
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piperaquine 1280 mg/day) [13].
Statistical analysis
The data were entered by Microsoft Office Excel 2007
and analysed by the Kaplan-Meier method [11,16]. The
patients of loss to follow-up and withdrawal from the
study were not involved into the analysis.
Ethical approval
According to the Helsinki Declaration, ethical approval
for the study was granted by the Ethics Committee of
Yunnan Institute of Parasitic Diseases, China. The pur-
pose of the study was explained and then approval was
sought from patients and their caretakers. Informed
written consent was obtained from patients or from
carers of child patients. All results were kept confidential
and were unlinked to any identifying information.
Results
During 2008–2013, a total of 750 vivax malaria patients
were recruited in the study, 14 withdrew, 133 were lost
at follow-up, and 603 completed valid follow-up, of
which 531 (88.1%) were Burmese (Table 2). The fever
clearance time (FCT) and asexual parasite clearance
times (APCT) were, respectively, 22.2 ± 10.2 and 38.1 ±
12.6 hours. The results showed that 594 (98.5%) of the
patients were ACPR, and nine (1.5%) LCF, without ETF
and LPF. Two LCF patients were observed in 2010, one
in 2012 and six in 2013 (Table 3). All nine LCF patients
responded well to the two-day treatment regimen of
dihydroartemisinin-piperaquine tablets. The result of
parasite sensitivity classification was the same as theTable 2 Baseline characteristics of vivax malaria patients in T
2008 (n = 22) 2009 (n = 9) 2010 (n = 84)
Sex
Male 20 (89.9%) 8 (88.9%) 63 (75.0%)
Female 2 (9.1%) 1 (11.1%) 21 (25.0%)
Nationality
Chinese 22 (100%) 9 (100%) 18 (21.4%)
Burmese 0 0 66 (78.6%)
Age (years)
Mean ± SD 20.2 ± 1.4 22.4 ± 4.8 28.4 ± 8.2
Range 23-50 31-53 2-59
Body temperature (°C)
Mean ± SD 38.1 ± 0.4 38.1 ± 0.8 38.5 ± 0.5
Rang 36.3-39.5 37.0-39.4 36.8-40
Parasite count (per μl)
Geometric mean 7,621 6,327 8,675
Range (per μl) 556-25,606 1,582-18,334 521-102,500treatment outcome. The number of susceptible parasites
was 594 and the RI was nine (Table 4). The PCR identi-
fied nine (1.5%) as recrudescence within day 28, one re-
crudescence on day 14 and 28, respectively, in 2010; one
on day 28 in 2012; one on day 14 and 21, respectively,
and four others on day 28 in 2013 (Tables 3 and 4). The
PCR did not identify any new infection of P. vivax. All
nine patients displaying RI and LCF were from the
neighbouring districts of Myanmar and no significant
differences were identified between different classifica-
tions. 1.5% (9/601) of LCF among imported cases from
Myanmar including 531 Burmese and 70 Chinese who
contracted malaria in Myanmar and come back to China
for treatment versus 0% (0/2) locally acquired in China
(x2 = 0.03, P = 0.862); 1.7% (9/531) of LFC in Burmese and
0% (0/72) in Chinese (x2 = 0.35, P = 0.552). 1.0% (3/287) of
LFC in adults (≥16 years) versus 1.9% (6/316) in children
(x2 = 0.28, P = 0.598).
Discussion
WHO encourages countries in which P. vivax is endemic
to carry out pilot studies to monitor CQ efficacy [11]. CQ
is the first-line drug for treatment of blood stage infection
of P. vivax and it has been used in treatment of vivax mal-
aria for more than 50 years in China. The study monitored
CQ therapeutic efficacy for uncomplicated vivax malaria
on the China-Myanmar border from 2008 to 2013. The
cumulative success rate for P. vivax treatment was 98.5%.
All nine treatment failures were LCF or RI resistance. Wei
et al. carried out a study on CQ therapeutic efficacy for P.
vivax treatment in China-Vietnam border from 1989 to
1998. They found P. vivax resistance to CQ in 1989 and
identified three RI, eleven RII and three RIII in the tenengchong and Yingjiang counties, Yunnan, China
2011 (n = 43) 2012 (n = 123) 2013 (n = 322) Total (n = 603)
28 (65.1%) 69 (56.1%) 165 (51.2%) 353 (58.5%)
15 (34.9%) 54 (43.9%) 157 (48.8%) 250 (41.5%)
10 (23.3%) 8 (6.5%) 5 (1.6%) 72 (11.9%)
33 (76.7%) 115 (93.5%) 317 (98.4%) 531 (88.1%)
33.5 ± 6.4 26.2 ± 10.2 18.3 ± 9.6 25.2 ± 6.8
2-60 2-59 1-60 1-60
39.3 ± 0.5 38.8 ± 0.6 38.2 ± 0.8 38.5 ± 0.7
37.1-41.0 36.6-40.0 36.5-40.8
6,732 8,976 8,156 7,881
663-99,130 546-111,960 586-97,846 521-111,960
Table 3 Treatment responses of vivax malaria patients in Tengchong and Yingjiang counties, Yunnan, China
2008 (n = 22) 2009 (n = 9) 2010 (n = 84) 2011 (n = 43) 2012 (n = 123) 2013 (n = 322) Total (n = 603)
ETF 0 0 0 0 0 0 0
LCF 0 0 2 (2.4%) 0 1 (0.8%) 6 (1.9%) 9 (1.5%)
LPF 0 0 0 0 0 0 0
ACPR 22 (100%) 9 (100%) 82 (97.6%) 43 (100%) 122 (99.2%) 316 (98.1%) 594 (98.5%)
Note: ETF = early treatment failure, LCF = late clinical failure, LPF = late parasitological failure, and ACPR = adequate clinical and parasitological response.
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47) [17]. Yang et al. observed 100 vivax malaria patients in
central Yunnan Province in 1995, two RI and two RII were
identified and the CFR was 4.0% (4/100) [18]. In the two
studies, patients with RI-RII P. vivax were subsequently
given a standard dosage of intramuscular artemether injec-
tions following the Ministry of Health’s recommended five-
day treatment regimen (160 mg on day 0 and 80 mg daily
for four days) [17,18]. Liang et al. reported one RI and CFR
1.9% (1/54) on the same China-Myanmar border in 2008.
They treated the CQ-resistant parasites with the two-day
treatment regimen of dihydroartemisinin–piperaquine tab-
lets [19]. Six CQ-resistant isolates were identified through
in vitro microtest in central China in 2005 [20]. The P.
vivax resistance to CQ was also found in Myanmar in
1990s [21-23]. Guthmann et al. reported that 34.1% (80/
235) of vivax malaria patients with CQ treatment had re-
current parasitaemia and were considered treatment fail-
ures in southern Myanmar between December 2002 and
April 2003 [24]. In other parts of the world, CQ resistance
in P. vivax has been documented across the Indonesian ar-
chipelago [25], South Korea [26], Turkey [27], the Horn of
Africa [28], and South America [29]. These studies showed
that there are increasing worldwide reports of CQ resist-
ance in P. vivax, however they did not indicate significant
change of CQ resistance [9,30].
The pace of CQ resistance development in P. vivax de-
pends on numerous factors, such as drug selective pres-
sure, endemicity, host immunity, and varies from region
to region. CQ was used for clinical and prophylactic treat-
ment of both P. vivax and Plasmodium falciparum in
China in 1980s. The drug policy was changed in response
to P. falciparum drug resistance, and then CQ was used
only for vivax malaria treatment since 1990s. This may be
one of reasons that the CFR (1.5%) of the study is much
lower than the CFR (37.1%) between 1989 and 1998 inTable 4 Clinical resistance of Plasmodium vivax in Tengchong
2008 (n = 22) 2009 (n = 9) 2010 (n = 84) 2011 (
S 22 (100%) 9 (100%) 82 (97.6%) 43 (100
R I 0 0 2 (2.4%) 0
R II 0 0 0 0
R III 0 0 0 0
Note: S = susceptible, RI = resistant level I, RII = resistant level II, RIII = resistant leveYunnan Province, China [17,18]. One of Wei et al. and
Yang et al. studies’ technical limitations was not to use PCR
to distinguish between re-infection and recrudescence to
confirm the Plasmodium species or to detect mixed infec-
tion, and to exclude microscopic misidentification of P fal-
ciparum as P vivax when P falciparum prevalence was
higher during 1989–98 and young ring stages difficult to
distinguish. These might have increased their CFRs. Yun-
nan is a large province, with Wei et al. doing their study on
the China-Vietnam border and Yang et al. in central Yun-
nan, whereas the current and other studies reported were
done on the China-Myanmar border. Geographic differ-
ences may be one of explanations for reported differences
too. Tengchong and Yingjiang are in a malaria-eliminating
phase, so PCR did not identify any new infection within
day 28. LCF of the study was observed in 2010, 2012 and
2013 and all nine LCF patients were imported from neigh-
bouring areas of Myanmar. This shows that CQ resistance
has not increased in recent years in Yunnan Province. CFR
1.9% (1/54) in 2008 [19], 2.4% (2/84) in 2010, 0.8% (1/123)
in 2012 and 1.9 (6/322) in 2013 showed that CQ resistance
did not significantly change (x2 = 0.86, P = 0.834) along the
China-Myanmar border.
Despite PCR being used to distinguish between re-
infection and recrudescence, to confirm the Plasmodium
species or to detect mixed infection in the study, P. vivax
can relapse from long-lasting liver stages [11,23]. It is one
limitation for the study and remains a challenge for moni-
toring in vivo P. vivax drug resistance. However, most of
P. vivax in tropical areas is usually an early relapsing strain
despite the late relapsing strain (temperate zone strains)
exists in some high altitude (around 3,000 metres above
the sea level) areas in Yunnan. The study was carried out
in tropical areas and most of malaria patients were in-
fected in Myanmar, so most of them should be tropical
strain or early relapsing strain. This would reduce the PCRand Yingjiang counties, Yunnan, China
n = 43) 2012 (n = 123) 2013 (n = 322) Total (n = 603)
%) 122 (99.2%) 316 (96.1%) 594 (98.5%)
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lapse. Another limitation of the study is the change of
surveillance sites, in Tengchong in 2008–2009, in both
Tengchong and Yingjiang in 2010–2011, and in Yingjiang
alone in 2012–2013. However, both monitoring sites are
in the same section of the China-Myanmar border, so the
study results indicate P. vivax sensitivity to CQ in the tar-
get region. The third limitation is that the number of valid
study cases was only 22 in 2008, nine in 2009 and 43 in
2011, which may be the reason that CQ resistance was not
found in those three years. The forth limitation is that
children < 1 year and over 60 years old persons were ex-
cluded from the study, so the results may not be applic-
able to these two age groups.
Conclusion
In terms of efficacy, CQ is still effective for vivax malaria
treatment. Plasmodium vivax CQ sensitivity has not sig-
nificantly changed on the China-Myanmar border of
Yunnan Province, China.
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